Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease

Metastatic basal cell carcinoma may be treated with hedgehog pathway inhibitors, including vismodegib and sonidegib. However, patients can demonstrate resistance to these agents. We describe a man with metastatic basal cell carcinoma who did not respond well to vismodegib and sonidegib. Next generat...

Full description

Bibliographic Details
Main Authors: Philip R. Cohen, Shumei Kato, Aaron M. Goodman, Sadakatsu Ikeda, Razelle Kurzrock
Format: Article
Language:English
Published: MDPI AG 2017-07-01
Series:International Journal of Molecular Sciences
Subjects:
basal
carcinoma
cell
cutaneous
immunotherapy
metastatic
nivolumab
Online Access:https://www.mdpi.com/1422-0067/18/8/1663

Internet

https://www.mdpi.com/1422-0067/18/8/1663

Similar Items